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Background: Subclinical deficiencies of vitamin K are universally present in unsupplemented cystic fibrosis (CF) patients. The dose required to
prevent deficiencies cannot be estimated from the existing literature. The aim of this study is determine if a supplemental dose of 1 mg/day or
5 mg/day vitamin K1 per day would normalize vitamin K status in a population of children with cystic fibrosis.
Methods: Fourteen pancreatic insufficient CF children, between the ages of 8 to 18 years old, were randomized to receive either 1mg/day or 5mg/day
vitamin K1 per day, for one month. Fasting blood tests were done at baseline and after one month of the intervention. The degree of
undercarboxylation of osteocalcin (%Glu-OC), and serum vitaminK1, were evaluated by descriptive statistics and nonparametricWilcoxonmatched-
pair test and Mann–Whitney U test.
Results: Of the 50% of subjects who were below the optimal serum vitamin K1 at baseline, all rose into the normal range with supplementation.
Supplementation also significantly reduced the overall %Glu-OC from a median of 46.8 to 29.1% (pb0.0003).
Conclusion: Our results suggest that both 1 mg and 5 mg of vitamin K1, given over a one-month period in pancreatic insufficient pediatric cystic
fibrosis patients improve vitamin K status.
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Subclinical deficiencies of vitamin K, at levels insufficient to
result in hemorrhage but great enough to impair the carboxyla-
tion of osteocalcin in bone, are considered universally present in
unsupplemented cystic fibrosis (CF) patients [1–3]. In a recent
cross-sectional survey, we observed subclinical vitamin K status
in 82% of pancreatic insufficient CF pediatric patients despite a
mean vitamin intake of 295±184 μg/day [4]. Vitamin K
insufficiency in cystic fibrosis is likely secondary to a
combination of fat malabsorption and decreased gut bacterial
menaquinone (vitamin K2) production because of chronic
antibiotic use. Possible liver disease, bowel resections, and⁎ Corresponding author. Tel.: +1 514 412 4400x22432; fax: +1 514 412 4250.
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doi:10.1016/j.jcf.2008.04.001increased mucous accumulation in the bowel [5] may also
increase the risk of vitamin K deficiency.
Although it has been concluded that vitamin K supplementa-
tion is necessary to prevent vitamin K deficiency in CF, the dose
required to prevent deficiencies cannot be estimated from the
existing literature and remains elusive. The 2002 consensus
report [6], which recommends 0.3–0.5 mg/day of supplemental
vitamin K in pediatric CF patients, was based on expert opinion
at the time and not on scientific evidence.
The aim of this study is to assess the effect of higher doses of
supplemental vitamin K on vitamin K status in pediatric CF
patients. The 1 mg/day dose was chosen as it is higher than the
current recommendations of 0.3–0.5 mg/day. Literature in
healthy adults has shown that a high phylloquinone intake of
1 mg/day is required to maximally carboxylate osteocalcin [7].
The 5 mg/day dose was chosen empirically.d by Elsevier B.V. All rights reserved.
Fig. 1. Change in percent undercarboxylated osteocalcin with vitamin K
supplementation.
Fig. 2. Change in vitamin K levels with supplementation.
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provides useful information on the adherence to vitamin K
supplement as well as its absorption.
Vitamin K is a cofactor for the carboxylation reaction that
transforms gamma-glutamyl residuals (Glu) residues to gamma
carboxyglutamate (Gla) residues. In subclinical vitamin K
deficiency, the undercarboxylated species of the vitamin K-
dependent proteins are released into the circulation. The percent
undercarboxylated osteocalcin (%Glu-OC) rises when vitamin
K status is suboptimal and has been found to be inversely
correlated with measures of bone quality [9,10], bone quantity
[10], and fracture risk [11].
2. Subjects and methods
Fourteen pancreatic insufficient CF children, between the
ages of 8 to 18 years old, were randomized to receive either
1 mg/day, or 5 mg/day, vitamin K1 for 1 month. Since no tablet
form of vitamin K1 is currently commercially available in
Canada, the injectable formulation of vitamin K1 – phytona-
dione (Sandoz Canada, Boucherville, Qc) – was diluted to
1 mg/ml and given orally. Injectable vitamin K1, given orally,
has recently been shown to be more effective than subcuta-
neous injections and as effective as intravenous administration
[12].
Of the seven subjects in each group, all completed the
intervention trial. One subject in the 5 mg group lost conscious-
ness at the time of the second blood procurement and hence no
blood work was drawn post-intervention, for this subject.
Exclusion criteria included any person who was pancreatic
sufficient, persons with known liver disease (diagnosed by
ultrasound, liver function tests and/or hepatomegaly) or any one
who was already receiving supplemental therapeutic vitamin K
K to treat coagulopathies.
Informed consent was obtained from a parent or guardian
and informed assent was obtained from all children participat-
ing in the study. Ethics approval was obtained from the
Institutional Review Board of McGill University.
Fasting blood tests were done at baseline and after one month
of the intervention. All vitamin supplementation was stopped24 h prior to blood procurement. The degree of under-
carboxylation of osteocalcin (%Glu-OC) was the primary
outcome measure as it is the most sensitive measure of overall
vitamin K nutritional status [13]. Success of the oral vitamin K1
intervention was defined as a %Glu-OC of less than 21%.
Undercarboxylated osteocalcin was determined by a standar-
dized hydroxyapatite binding assay and radioimmunoassay
(RIA) in the laboratory of Dr. Caren Gundberg [14].
Fasting serum vitamin K levels were measured by high
performance liquid chromatography (HPLC) with post-column
reduction and fluorimetric detection. This assay is sensitive to a
lower limit of 0.03 nmol/L; non-detectable samples were
assigned this value.
Undercarboxylated osteocalcin and serum vitamin K were
analyzed by descriptive statistics and nonparametric Wilcoxon
matched-pair test and the Mann–Whitney U test for change at
the end of the one-month intervention with either 1 mg/day or
5 mg/day supplementation.
The sample size calculation was based on an expected
reduction in %Glu-OC of 13% (from 33% down to 20%) [4]
with supplementation. The coefficient of variation (CV) of the
%Glu-OC assay is reported to be 8%. This study was not
powered to detect statistical difference between the 1 mg and
5 mg dose of supplementation.
3. Results
All %Glu-OC levels (14/14) were elevated, as defined as
greater than 21%, prior to the vitamin K1 supplementation
(Fig. 1). Similarly, 50% (7/14) of the baseline vitamin K levels
were suboptimal (defined as b0.3 nmol/L) at baseline with 43%
(6/14) of all the vitamin K levels being undetectable
(b0.03 nmol/L) (Fig. 2). Three of these undetectable levels
were found in subjects taking a non-vitamin K containing
multivitamin and three in those on ADEK™, a multivitamin
which provides 150 µg/tablet vitamin K1. Supplementation with
vitamin K1 for 1 month significantly reduced the overall %Glu-
OC from a median of 46.8 to 29.1% (pb0.0003). Three of
the 13 (23%) undercarboxylated osteocalcin levels decreased
into the normal (Fig. 1)—one in the 5 mg/day group and two in
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significantly (pb0.001) with supplementation and all subjects
who were below the optimal range (0.3 nmol/L) rose into the
normal range with supplementation (Fig. 2). There was no trend
towards a difference between the 5 mg/day vitamin K1 and the
1 mg/day in terms of change in %Glu-OC or in the change in
serum vitamin K.
4. Discussion
Subclinical deficiencies of vitamin K are widespread in both
supplemented and unsupplemented CF patients alike. After one
month of supplementation, there was a highly significant
improvement in vitamin K status, as assessed by the under-
carboxylated osteocalcin (%Glu-OC), but in both the 1 mg/day
and the 5 mg/day supplemented groups, the majority of patents
remained in the suboptimal range. It is possible that the duration
of the supplementation was not long enough to normalize the
vitamin K status. In a 3-year vitamin K2 intervention trial in
postmenopausal women, the %Glu-OC decreased markedly up
until the 3-month intervention period and then remained
unchanged until the end of the study [15].
Beker et al. [16] supplemented CF patients with 5 mg
vitamin K1 per week for 4 weeks and found that the vitamin K
supplementation improved, but did not normalize vitamin K
parameters. Nicolaidou et al. [17] supplemented CF patients
with 10 mg/week for 1 year and found significant improvement
in %Glu-OC, but it is difficult to compare results from different
studies using different methods for assessing %Glu-OC.
In conclusion, our results suggest that higher doses of
vitamin K1 than presently recommended, given over a one-
month period, improve vitamin K status. The 5 mg/day dose did
not appear to offer an advantage over the 1 mg/day dose. A
longer period of supplementation may be needed to achieve
normal vitamin K status. There is a need for long-term vitamin
K1 intervention trials to shed further light on preventing and
treating this widespread nutrient deficiency affecting CF
patients.
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